Join to View Full Profile
1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-8580
Fax+1 404-778-1215
Dr. Hofmeister is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Craig Hofmeister is an oncologist based in Atlanta, GA, specializing in hematologic oncology with expertise in amyloidosis, multiple myeloma, and hematopoietic stem cell transplantation. He completed his medical and fellowship training at Loyola University Medical Center and holds an MPH in Clinical Investigation from Ohio State University. Currently, he is an Associate Professor at Emory University Hospital. Dr. Hofmeister has contributed to multiple publications on multiple myeloma and leads clinical trials focusing on personalized treatments and novel therapies for this condition. He spends most of his time as a 'translational informaticist', working to maximize Epic for research.
Education & Training
Ohio State UniversityMPH, Clinical Investigation, 2009 - 2012
Loyola University Medical CenterFellowship, Hematopoietic Stem Cell Transplantation, 2005 - 2006- Loyola University Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
- Loyola University Medical CenterResidency, Internal Medicine, 1999 - 2002
Ohio State University College of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2017 - 2027
LA State Medical License 2020 - 2022
NC State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
OH State Medical License 2006 - 2018
IL State Medical License 1999 - 2008
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- Business First’s Forty Under 40 Award Columbus Dispatch, 2011
Clinical Trials
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma Start of enrollment: 2004 Jul 01
- Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease Start of enrollment: 2003 Jul 01
- Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation Start of enrollment: 2004 Feb 01
Publications & Presentations
PubMed
- 1 citationsInfection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.Lorenzo Cani, Sara A Scott, Danielle Roberts, Nisha S Joseph, Craig C Hofmeister
Haematologica. 2026-02-01 - Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-h...Noffar Bar, Thomas Martin, Craig C Hofmeister, Maria-Victoria Mateos, Markus Hansson
Leukemia. 2026-01-07 - 3 citationsEarly CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.Alyssa M Duffy, Anshika Goenka, Maryam I Azeem, Azmain Taz, Sayalee V Potdar
The Journal of Clinical Investigation. 2025-10-01
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
- Evidence Does Not Support Clinically Significant Lenalidomide-CCI-779 Interaction via P-Glycoprotein ReplyHofmeister,CC; Yang,X; Phelps,MA, Journal of Clinical Oncology, 1/1/2012
- Evaluation of pulmonary infiltrates in post stem cell transplant patientsScaglione S, Hofmeister CC, Stiff PJ, Hematology, 12/1/2005
Abstracts/Posters
- Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple MyelomaCraig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Craig C Hofmeister, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
When Is Treating a Precursor Condition Harmful?October 8th, 2024- Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual MeetingMay 29th, 2020
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational HighlightsMarch 5th, 2020
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
